Business

Know the Business

Centene is a $195B-revenue managed care organization that earns its keep as the middleman between government health programs and the providers who actually deliver care. The market most likely underestimates the durability of Centene's Medicaid franchise and the margin recovery runway across all three segments, while overestimating the structural risk from Marketplace membership contraction. What matters most: can management restore the Health Benefits Ratio to pre-2025 levels while navigating unprecedented policy churn?

How This Business Actually Works

Centene collects capitated premiums from government payers — state Medicaid agencies, CMS for Medicare/PDP, and the ACA Marketplace via premium subsidies — and pays providers to deliver care. The spread between premium revenue and medical costs (the Health Benefits Ratio, or HBR) is the entire economic engine. SG&A runs 7–8% of revenue; operating margins are structurally thin at 1–3%.

The business model has three distinctive features:

Capitation = fixed revenue, variable cost. Centene receives a fixed per-member-per-month (PMPM) payment regardless of what members actually consume. Every dollar of medical cost above the capitation rate comes straight out of margin. This makes the HBR the single most important number in the company.

Government as sole customer. Over 95% of revenue comes from government contracts. Pricing power is limited — rates are set by state actuaries (Medicaid) or CMS (Medicare/PDP). Centene's only levers are (1) advocating for actuarially sound rates, (2) managing medical costs through utilization management, network design, and fraud/waste/abuse programs, and (3) operating more efficiently than peers.

Scale advantage is real but narrow. Centene operates in 30 states with local brands and local teams. Scale helps with data aggregation (spotting fraudulent providers across state lines), SG&A leverage (7.4% in FY2025 vs. 8.5% in FY2024), and negotiating provider contracts. But each state contract is a separate negotiation with its own rules, benefit designs, and rate-setting processes. National scale does not translate into national pricing power.

Revenue nearly tripled from $60B to $195B in seven years, driven by the WellCare acquisition (2020), ACA Marketplace expansion, and the PDP scale-up under IRA changes. Organic growth runs 5–7% annually; the rest has been acquisitive.

The Playing Field

The peer comparison reveals three things:

Centene trades at the deepest discount in the sector. At 0.13x revenue, CNC is valued at roughly one-sixth of UNH's multiple and half of Molina's. This reflects the FY2025 earnings collapse (goodwill impairment, elevated HBR) and market skepticism about the margin recovery trajectory.

Molina is the closest comparable. Both are pure-play government-sponsored MCOs. Molina's higher multiple (~0.26x) reflects better recent margin execution and a smaller, arguably more manageable footprint. When CNC's Medicaid margins normalize, this valuation gap should narrow.

UNH's premium reflects Optum, not just insurance. UNH's health services business (Optum) generates higher-margin, less cyclical revenue. CNC has no equivalent vertical integration play — its "Other" segment (specialty pharmacy, Magellan) is being divested, not built.

Is This Business Cyclical?

Managed Medicaid is not cyclical in the traditional sense — demand grows during recessions as more people qualify for government programs. But the business has its own distinct cycle driven by three forces:

1. Policy-driven membership cycles. COVID continuous enrollment inflated Medicaid membership by ~3.6M members. Redeterminations (starting March 2023) then shed members, shifting acuity higher. The OBBBA (July 2025) adds work requirements and more frequent eligibility checks, creating another membership churn wave in 2027+.

2. Rate-lag cycles. Medical costs rise first; rates catch up 6–18 months later. The FY2025 HBR spike to 91.9% (from 88.3% in FY2024) happened because behavioral health and high-cost drug trends accelerated faster than state actuaries adjusted rates. Q1 2026 Medicaid HBR of 93.1% (50bps better YoY) shows the catch-up beginning.

3. Marketplace regulatory cycles. Enhanced APTCs expired end of 2025, contracting Marketplace membership from 5.5M to ~3.6M and shifting the risk pool sicker. CNC repriced aggressively (mid-30% rate increases) and expects risk adjustment to offset higher Silver-tier acuity.

The FY2025 GAAP loss is misleading. Strip out the $6.7B goodwill impairment, and adjusted EPS was $2.08. The real story: operating margins compressed from ~2% to near-zero on a normalized basis in FY2025, and the question is how fast they recover. Q1 2026 (adj EPS $3.37, guidance raised to more than $3.40) suggests the recovery is real and accelerating.

The Metrics That Actually Matter

HBR is the only metric that truly matters. At $195B in revenue, every 100 basis points of HBR improvement generates roughly $1.7B in pretax income. The entire investment thesis reduces to: will the HBR normalize from 91.9% back toward 88–89%? Management's Q1 2026 Medicaid HBR of 93.1% (down from 93.6% a year ago) and full-year guidance of 90.9–91.7% suggest progress, not completion.

Medicaid rate yield vs. net trend is the margin engine's fuel gauge. Management targets mid-4% for both, meaning rates and costs are matched. Any positive spread drives incremental margin. Q1 2026 showed fundamental outperformance from trend management initiatives beyond just favorable flu and weather effects.

Marketplace risk adjustment receivable/payable is new critical variable. CNC shifted from expecting a payable to a "slight receivable" for 2026. June Wakely data will determine if the full offset materializes — potentially lifting Marketplace margins from the guided ~3% to 4%+.

Days in claims payable (DCP) is the balance-sheet metric to watch. At 48 days (Q1 2026), it signals conservative reserving. Any material decline would suggest reserve releases or under-reserving.

What I'd Tell a Young Analyst

This is a margin-recovery story, not a growth story. Revenue growth is largely mechanical (PDP premium inflation from IRA changes, Medicaid rate increases). The stock will move on basis points of HBR, not billions of revenue.

Watch three things this year: (1) June Wakely data for Marketplace risk adjustment — this is the single biggest near-term catalyst. (2) Medicaid HBR progression through Q2–Q3 — management said they'd be "disappointed" if full-year Medicaid HBR doesn't beat 93.7%. (3) Medicare Advantage path to breakeven in 2027 — getting the bids right is existential for that segment.

The market is pricing in permanent impairment. At ~$54/share and a $26B market cap, CNC trades at less than 16x the $3.40+ adjusted EPS guidance for 2026, which management has called a "rebuilding year." If normalized earnings power is $6–7+ (roughly FY2024 levels), the stock is deeply undervalued. The bear risk is that medical cost trend stays elevated and rates never fully catch up.

Policy risk is the permanent overhang. Medicaid work requirements (OBBBA), provider tax changes (2028), and Marketplace program integrity rules create a constant stream of membership and margin uncertainty. This is why CNC always trades at a government-contractor discount. The offset: CMS dual-eligible integration rules (2027–2030) should be a structural tailwind for CNC's overlapping Medicaid/Medicare footprint.

Don't confuse the GAAP loss with the business. FY2025's $6.7B goodwill impairment and $13.53 GAAP loss per share were a non-cash write-down of overpaid acquisition goodwill (WellCare, Magellan), not an operating catastrophe. Adjusted EPS was $2.08. The market knows this, but the GAAP headline still depresses sentiment.